Table 1.
Demographic and Clinical Profile of HCM Patients with TWA(+) and TWA(–)
| Parameter | TWA(–) n = 42 | TWA(+) n = 46 | P‐Value |
|---|---|---|---|
| Age (years) | 49.52 ± 16.36 | 53.98 ± 10.84 | 0.160 |
| Gender (F/M) | 24/18 | 11/35 | 0.001 |
| Family history of SCD | 6 (14.3%) | 12 (26.1%) | 0.06 |
| Syncope | 6 (14.3%) | 31 (67.4%) | <0.001 |
| NYHA class II | 17 (40.5%) | 28 (60.9%) | 0.04 |
| NT‐proBNP (pg/mL) | 165.2 ± 59.2 | 445.7 ± 223.9 | <0.001 |
| IVS (mm) | 21.7 ± 3.9 | 22.02 ± 4.19 | 0.7 |
| LV mass (g) | 319.6 ± 103.87 | 329.4 ± 83.7 | 0.5 |
| LVEF (%) | 57.4 ± 7.9 | 56.3 ± 7.3 | 0.9 |
| Patients with LVOT gradient >30 mmHg | 8 (19%) | 31 (67.4%) | <0.001 |
| Patients with abnormal BP response | 19 (45.2%) | 20 (43.4%) | 0.9 |
BP= blood pressure; IVS = interventricular septum thickness; LVEF = left ventricular ejection fraction; LVOT = left ventricular outflow tract; NT‐proBNP = N‐terminal precursor of brain natriuretic peptide; SCD = sudden cardiac death.